A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation

Study Description

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to determine the safety and effectiveness of prucalopride in the treatment of Filipino patients with chronic constipation whom prior laxatives fail to provide adequate relief.

Condition or disease	Intervention/treatment
Chronic Constipation	Drug: Prucalopride

Detailed Description:

This is a 12-week open label (all people know the identity of the intervention), multi-center, prospective (the patients are identified and then followed forward in time for the outcome of the study) observational study assessing the safety and effectiveness of prucalopride among Filipino patients with chronic constipation. Chronic constipation is a condition in which bowel movements are infrequent or incomplete for a prolonged time. The use of prucalopride should be used in accordance with the approved product label and will follow the normal medical practice of the investigators. Patients should take 2 mg prucalopride tablet orally once daily. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given. Patients will be asked to fill-up a patient diary daily for 12-weeks to monitor the bowel movement during the study period. All adverse events and concomitant medications taken by the patients during the study will be documented accordingly. Patients will be monitored during the 12-week period of observation while the patients are in prucalopride treatment.

Study Design

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Observational
Actual Enrollment :	0 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	A Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation
Study Start Date :	February 2013
Estimated Primary Completion Date :	February 2014
Estimated Study Completion Date :	December 2014

Groups and Cohorts

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort	Intervention/treatment
Prucalopride	Drug: Prucalopride; Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.

Outcome Measures

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. The incidence of patients discontinuing treatment due to adverse events, serious adverse events, or adverse drug reactions [ Time Frame: 12 weeks ]

Secondary Outcome Measures :

1. The percentage of patients having at least 3 spontaneous complete bowel movements (SCBM) in a week after treatment with prucalopride [ Time Frame: 12 weeks ]
   SCBM is defined as a sense of complete evacuation of bowel without straining.
2. The change from baseline in the Patient Assessment of Constipation Symptoms (PAC-SYM) score after treatment with prucalopride [ Time Frame: Baseline, 12 weeks ]
   The PAC-SYM questionnaire is a 12-item survey that measures constipation symptoms and associated severity across three domains: stool symptoms, rectal symptoms, and abdominal symptoms. Symptom items are rated on a 5-point Likert severity scale. Item values are scored from 0 to 4, with 0 indicating absence of symptom, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe indicating the worst severity of that symptom.

Eligibility Criteria

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Filipino patients with chronic constipation

Criteria

Inclusion Criteria:

• Diagnosis of chronic constipation by history and physical examination, including rectal exam
• History of chronic constipation not satisfied with laxatives
• Patient reports, on average, 2 or fewer spontaneous bowel movements (SBMs) per week and 1 or more of the following for the last three months: very hard (little balls) and/or hard stools in more than 25% of bowel movements (BMs); sensation of incomplete evacuation in more than 25% of BMs; straining at defecation in more than 25% of BMs; sensation of ano-rectal obstruction or blockade in more than 25% of BMs; a need for digital manipulation to facilitate evacuation in more than 25% of BMs
• Females of childbearing potential agree to use highly effective contraceptive methods

Exclusion Criteria:

• Renal impairment requiring dialysis
• Secondary chronic constipation and organic gastrointestinal (GI) disorders
• Intestinal perforation / obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory condition of the intestinal tract such as Crohn's disease, ulcerative colitis, toxic megacolon / rectum
• Hypersensitive to Prucalopride or to any of its components
• Patients receiving concomitant drugs known to cause QTc prolongation
• Pregnant or lactating

Contacts and Locations

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Philippines
Makati City, Philippines
Manila, Philippines
Marikina City, Philippines
Muntinlupa, Philippines
Quezon City, Philippines
San Juan, Philippines
Taguig, Philippines

Sponsors and Collaborators

Janssen Pharmaceutica

Investigators

Study Director:	Janssen Pharmaceutica Clinical Trial	Janssen Pharmaceutica

More Information

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Janssen Pharmaceutica
ClinicalTrials.gov Identifier:	NCT01692132 History of Changes
Other Study ID Numbers:	CR017521; PRUCOP4001 ( Other Identifier: Janssen Pharmaceutica )
First Posted:	September 25, 2012
Last Update Posted:	December 2, 2015
Last Verified:	November 2015

Keywords provided by Janssen Pharmaceutica:

Chronic Constipation; Prucalopride; Post Marketing Surveillance

Additional relevant MeSH terms:

Constipation; Signs and Symptoms, Digestive; Signs and Symptoms